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Introduction
Steroid-5-alpha-reductase inhibitors are commonly used in
the treatment of benign prostatic enlargement and male
alopecia with controversial results. Ethnic diversity is an
important factor, accounting for interindividual variation in
drug responsiveness. The aim of this study was to evaluate
the genotypic distribution of 22 SNPs in steroid-5-alpha-
reductase alpha polypeptides 1 and 2 in a set of 601 prostate
cancer patients from four different Spanish regions. The
genotyping was done in a Biotrove OpenArray NT Cycler.
∗For correspondence. E-mail: lhenriquez@dcc.ulpgc.es.
Twelve SNPs of 22 analysed were differentially distributed
among the different regions. Since all subjects were Cau-
casian of Spanish origin, this result showed differences in
genotype distribution among subject from the same ethnic
origin. These observations were confirmed in cluster analy-
sis, principal component analysis and in the differential dis-
tribution of haplotypes among the populations. Differences
in distribution of genotypes within different populations of
the same ethnicity could be an important factor responsi-
ble for the wide variety of pharmacological responses to
steroid-5-alpha-reductaseinhibitors.
Prostate cancer (PCa) is a hormone-dependent tumour
which needs androgens for disease initiation and progression
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(Huggins 1967). Although, testosterone (T) is the most abun-
dant serum androgen, dihydrotestosterone (DHT) is the main
prostate androgen. T is converted to DHT by the enzyme
steroid-5-alpha-reductase (SRD5A) in the prostate, testes,
hair follicles and adrenal glands (McConnell 1995). Since
the discovery of the implications of SRD5A2 deficiency, it
has been an increasing interest in the development of steroid-
5-alpha-reductase inhibitors (5α-RI). Among several com-
pounds, only two drugs have been FDA approved for clinical
use: finasteride, which inhibits SRD5A2 and was approved
for the treatment of benign prostatic enlargement (BPE) and
male alopecia; and dutasteride, which inhibits SRD5A1 and
SRD5A2 (approved for the treatment of BPE) (Edwards and
Moore 2002; Andriole and Kirby 2003). Nowadays, duta-
steride and finasteride do not prevent CaP, but merely tem-
porarily shrink tumours that have a low potential for being
lethal (Walsh 2010).
The enzymatic activity of SRD5A is highly modulated
by single-nucleotide polymorphisms (SNPs) located in these
genes (Giwercman et al. 2005; Cussenot et al. 2007). These
genetic variations in key genes belonging to the androgen
pathway seem to be important for the prostate response
to androgens (Lindstrom et al. 2006). We have recently
reported that differences in the distribution of genotypes
within different populations of the same ethnicity could
be an important confounding factor in association studies
(Henriquez-Hernandez et al. 2013a).
We designed a study aimed to evaluate the genotypic dis-
tribution of 22 SNPs in SRD5A1 and SRD5A2 in a set of
Spanish prostate cancer patients, to determine the homogene-
ity of the population and to disclose potential bias associated
with the failure of 5α-RI when prescribed.
Materials and methods
A total of 601 patients with nonmetastatic localized prostate
cancer were included in this study. Geographical distribution
of patients was as follows (Henriquez-Hernandez et al. 2013a):
91 (15.14%) from Andalusia, 51 (8.48%) from Basque Country,
238 (39.60%) from Canary and 221 (36.77%) from Cat-
alonia. All patients were of Spanish origin and all of them
received written informed consent before sample collection.
Ethnicity of patients was established until the second parental
generation. This study was approved by the Research and
Ethics Committee of each institution participant in the study.
DNA was isolated from 300 µL of whole-blood in
an iPrepTM purification instrument using the iPrepTM
PureLinkTM gDNA Blood kit (Invitrogen, Life Technologies,
Carlsbad, USA). DNA integrity was determined by Nano-
Drop ND-1000 (NanoDrop Technologies, Wilmington, USA).
SNPs were selected using data of individuals with Euro-
pean ancestry (CEU) from the HapMap Project (available
at: http://www.hapmap.org). Pairwise linkage disequilibrium
(LD) tagging was achieved with Haploview ver. 4.2 soft-
ware (free downloaded from http://www.broadinstitute.org/
scientific-community/science/programs/medical-and-population-
genetics/haploview/haploview) (Barrett et al. 2005). The R2
given by Haploview was >0.95 for all genes. Description
of SNPs is provided in table 1 in electronic supplementary
material at http://www.ias.ac.in/jgenet/.
The SNP genotyping was performed in a Biotrove
OpenArray R© NT Cycler (Applied Biosystems, Foster City,
USA) following the instructions of manufacturer (Henriquez-
Hernandez et al. 2013b). The fluorescence results were read
using the OpenArray R© SNP genotyping analysis software
ver. 1.0.5 (Applied Biosystems). The genotyping analysis
was performed using TaqMan Genotyper software ver. 1.0.1
(available at: http://www.invitrogen.com/site/us/en/home/Glo
bal/forms/taqman-genotyper-software-download-reg.html)
using autocalling as the call method. The quality value of the
data points was determined by a threshold above 0.95. Geno-
typing analysis was done for each population separately and
it was done automatically without any manual assignment
of genotypes as previously reported (Henriquez-Hernandez
et al. 2013a). All the genotyped samples met the quality
criteria and all samples were genotyped with the same batch
of material and at the same time.
Genotype and allelic frequencies were determined using
the web-based environment SNPator (SNP Analysis To
Results, from the Spain’s National Genotyping Center and
the National Institute for Bioinformatics) (Morcillo-Suarez
et al. 2008).
Principal component analysis (PCA) was done using
SnpMatrix and XSnpMatrix classes and methods (Clayton
2012), implemented as an R package and available from
Bioconductor (as of ver. 2.11; http://bioconductor.org). Non-
supervised hierarchical clustering of SNP in each population
was done using MultiExperiment Viewer ver. 4.9 (available
at: http://www.tigr.org).
Results
A total of 601 PCa patients were genotyped for 22 SNPs;
10 SNPs located in SRD5A1 gene and 12 SNPs located
in SRD5A2 gene. Of the 13,222 possible determinations,
94.31% were successfully genotyped.
The genotypic and allelic frequencies are shown in table 1.
The genotype distribution was different among the study
populations in 12 of the 22 SNPs: rs166050, rs501999,
rs518673, rs3822430, rs8192120, rs39848 (SRD5A1); and
rs2208532, rs12470143, rs2281546, rs3754838, rs523349,
rs9332975 (SRD5A2) (χ2 test, table 1), showing a differen-
tial distribution of genotypes among populations.
A nonsupervised hierarchical cluster was performed to
visualize the genotype distributions among the four popu-
lations. For SRD5A1, polymorphisms were distributed into
three main clusters, each one with different numbers and iden-
tities of SNPs, suggesting heterogeneity among populations
(figure 1 in electronic supplementary material, left panel).
For SRD5A2, SNPs were distributed into two main clusters,
very similar for Basque, Canary and Catalan populations,
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Table 1. Genotype and allelic frequencies of SRD5A1 and SRD5A2 gene polymorphisms among the populations.
Call rate Genotype Allele Functional consequence MAF
SRD5A1
rs166050 AA AG GG A G Intron variation 0.12
Andalusia 0.75 0.65 0.21 0.14 0.75 0.25
Basque Country 0.98 0.52 0.42 0.06 0.73 0.27
Canary 0.99 0.62 0.33 0.05 0.79 0.21
Catalonia 0.94 0.57 0.37 0.06 0.76 0.24
P value 0.025
rs501999 CC CT TT C T Intron variation 0.49
Andalusia 0.70 0.48 0.20 0.32 0.59 0.41
Basque Country 1.00 0.29 0.49 0.22 0.54 0.46
Canary 0.99 0.29 0.49 0.22 0.53 0.47
Catalonia 0.98 0.30 0.43 0.27 0.51 0.49
P value 0.003
rs518673 AA AG GG A G Intron variation 0.32
Andalusia 0.75 0.19 0.19 0.62 0.29 0.71
Basque Country 1.00 0.16 0.37 0.47 0.34 0.66
Canary 0.96 0.07 0.42 0.51 0.28 0.72
Catalonia 0.96 0.10 0.40 0.50 0.30 0.70
P value 0.006
rs3822430 AA AG GG A G Synonymous codon 0.30
Andalusia 0.77 0.37 0.24 0.39 0.49 0.51
Basque Country 1.00 0.27 0.61 0.12 0.58 0.42
Canary 0.97 0.33 0.51 0.16 0.58 0.42
Catalonia 0.97 0.37 0.47 0.16 0.60 0.40
P value <0.001
rs500182 GG GT TT G T Intron variation 0.20
Andalusia 0.81 0.01 0.14 0.85 0.08 0.92
Basque Country 1.00 0.02 0.18 0.80 0.11 0.89
Canary 0.98 0.01 0.17 0.82 0.09 0.91
Catalonia 0.99 0.01 0.18 0.81 0.10 0.90
P value 0.961
rs8192120 AA AC CC A C Intron variation 0.43
Andalusia 0.80 0.14 0.22 0.64 0.25 0.75
Basque Country 0.99 0.08 0.42 0.50 0.29 0.71
Canary 0.97 0.10 0.42 0.48 0.31 0.69
Catalonia 0.98 0.10 0.48 0.42 0.34 0.66
P value 0.015
rs4702378 CC CT TT C T Intron variation 0.24
Andalusia 0.82 0.07 0.23 0.70 0.18 0.82
Basque Country 1.00 0.06 0.20 0.74 0.16 0.84
Canary 0.99 0.04 0.33 0.63 0.21 0.79
Catalonia 0.99 0.06 0.33 0.61 0.23 0.77
P value 0.304
rs1691053 AA AG GG A G NA 0.15
Andalusia 0.87 0.90 0.09 0.01 0.95 0.05
Basque Country 1.00 0.90 0.08 0.02 0.94 0.06
Canary 0.98 0.86 0.13 0.01 0.93 0.07
Catalonia 0.99 0.85 0.15 0.00 0.93 0.07
P value 0.341
rs39848 CC CT TT C T Downstream variant 0.43
Andalusia 0.70 0.32 0.22 0.46 0.43 0.57
Basque Country 0.96 0.22 0.43 0.35 0.44 0.56
Canary 0.97 0.11 0.50 0.39 0.36 0.64
Catalonia 0.94 0.16 0.45 0.39 0.39 0.61
P value <0.001
rs3797179 AA AG GG A G Intron variation 0.12
Andalusia 0.70 0.00 0.17 0.83 0.09 0.91
Basque Country 0.96 0.00 0.29 0.71 0.14 0.86
Canary 0.99 0.05 0.25 0.70 0.17 0.83
Catalonia 0.96 0.03 0.26 0.71 0.17 0.83
P value 0.213
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Table 1 (contd)
Call rate Genotype Allele Functional consequence MAF
SRD5A2
rs2208532 AA AG GG A G Intron variation 0.44
Andalusia 0.70 0.45 0.28 0.27 0.59 0.41
Basque Country 0.99 0.20 0.42 0.38 0.41 0.59
Canary 0.99 0.34 0.46 0.20 0.57 0.43
Catalonia 0.92 0.28 0.54 0.18 0.55 0.45
P value 0.001
rs12470143 CC CT TT C T Intron variation 0.37
Andalusia 0.81 0.45 0.24 0.31 0.57 0.43
Basque Country 1.00 0.26 0.53 0.21 0.52 0.48
Canary 0.99 0.32 0.51 0.17 0.57 0.43
Catalonia 0.98 0.29 0.54 0.17 0.56 0.44
P value 0.001
rs2281546 GG GT TT G T Intron variation 0.17
Andalusia 0.83 0.09 0.07 0.85 0.12 0.88
Basque Country 1.00 0.00 0.27 0.73 0.14 0.86
Canary 0.99 0.03 0.22 0.75 0.14 0.86
Catalonia 0.99 0.02 0.25 0.73 0.14 0.86
P value 0.001
rs3754838 CC CT TT C T NA 0.12
Andalusia 0.78 0.10 0.11 0.79 0.16 0.84
Basque Country 1.00 0.00 0.23 0.77 0.12 0.88
Canary 0.96 0.03 0.20 0.77 0.12 0.88
Catalonia 0.98 0.02 0.20 0.78 0.12 0.88
P value 0.010
rs4952222 AA AC CC A C Intron variation 0.04
Andalusia 0.85 0.00 0.01 0.99 0.01 0.99
Basque Country 1.00 0.00 0.00 1.00 0.00 1.00
Canary 0.99 0.00 0.00 1.00 0.00 1.00
Catalonia 0.97 0.00 0.00 1.00 0.00 1.00
P value 0.086
rs7562326 CC CT TT C T Intron variation 0.14
Andalusia 0.80 0.05 0.12 0.83 0.12 0.88
Basque Country 1.00 0.00 0.23 0.77 0.12 0.88
Canary 0.98 0.03 0.20 0.77 0.13 0.87
Catalonia 0.97 0.02 0.21 0.77 0.12 0.88
P value 0.321
rs2300702 CC CG GG C G Intron variation 0.45
Andalusia 0.81 0.28 0.34 0.38 0.45 0.55
Basque Country 0.96 0.12 0.49 0.39 0.37 0.63
Canary 0.99 0.21 0.47 0.32 0.44 0.56
Catalonia 0.94 0.16 0.50 0.34 0.41 0.59
P value 0.127
rs4952197 AA AG GG A G Intron variation 0.25
Andalusia 0.80 0.12 0.19 0.69 0.22 0.78
Basque Country 0.99 0.04 0.28 0.68 0.18 0.82
Canary 0.99 0.06 0.31 0.63 0.22 0.78
Catalonia 0.97 0.06 0.36 0.58 0.24 0.76
P value 0.117
rs676033 CC CT TT C T NA 0.35
Andalusia 0.81 0.57 0.31 0.12 0.72 0.28
Basque Country 0.99 0.60 0.32 0.08 0.76 0.24
Canary 0.99 0.50 0.39 0.11 0.70 0.30
Catalonia 0.98 0.50 0.43 0.07 0.71 0.29
P value 0.402
rs523349 CC CG GG C G Missense 0.35
Andalusia 0.78 0.55 0.27 0.18 0.68 0.32
Basque Country 0.92 0.64 0.32 0.04 0.80 0.20
Canary 0.71 0.18 0.52 0.30 0.45 0.55
Catalonia 0.89 0.52 0.40 0.08 0.72 0.28
P value <0.001
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Table 1 (contd)
Call rate Genotype Allele Functional consequence MAF
rs9332975 CC CT TT C T utr variant 0.14
Andalusia 0.77 0.10 0.07 0.83 0.14 0.86
Basque Country 1.00 0.00 0.26 0.74 0.13 0.87
Canary 0.99 0.03 0.19 0.78 0.13 0.87
Catalonia 0.98 0.02 0.20 0.78 0.12 0.88
P value 0.002
rs7594951 CC CT TT C T Intron variation 0.11
Andalusia 0.75 0.84 0.10 0.06 0.89 0.11
Basque Country 1.00 0.76 0.24 0.00 0.88 0.12
Canary 0.99 0.77 0.20 0.03 0.88 0.12
Catalonia 0.98 0.78 0.20 0.02 0.88 0.12
P value 0.193
MAF, minor allele frequency; NA, not available. Functional consequence and MAF are available at: http://www.ncbi.nlm.nih.gov/projects/
SNP/. Differences in the genotype distribution were assessed by χ2 test.
but clearly different from Andalusian population (figure 1
in electronic supplementary material, right panel). PCA was
performed to identify global differences among populations.
Components 1, 2 and 3 were responsible for the 43.7%,
22.6% and 15.3% of the variance for SRD5A1, respectively
(cumulative percentage: 81.6%); and 48.8%, 33.2% and
9.1% of the variance for SRD5A2 gene, respectively (cumu-
lative percentage: 91.1%). The first component distinguished
between the populations for both genes clearly showed the
differences in the distribution of genotypes between the
analysed populations (figure 1).
Haplotype analysis was performed in SNPator. For
SRD5A1 (chromosome 5), the haplotype GCCTATGGCA
was only present among the Andalusian subjects. For
SRD5A2 (chromosome 2), there is a greater homogeneity in
the distribution of haplotypes. The fact that the most frequent
haplotypes were equal in all populations suggests a similarity
between individuals of the same ethnicity.
Discussion
We have recently reported differences in the distribution
of genotypes within different populations of the same eth-
nicity (Henriquez-Hernandez et al. 2013a), highlighting the
importance of ethnic-specific differences in drug respon-
siveness (Yasuda et al. 2008; Ma and Lu 2011). In the
present paper, we observed that genotype distribution of
12 of 22 SNPs were statistically different among the stud-
ied populations. The Spanish population is considered as
Caucasian. However, the natural history of each subpopu-
lation is different, and there is a high complexity in the
Mediterranean migration processes that impact in the dif-
ferent population sources on the genetic composition of the
Spanish population (Ambrosio et al. 2010). While Andalu-
sian population seems to be originated by migrations from
Arabian Peninsula, Fertile Crescent, Balkan region and
North Africa (Ambrosio et al. 2010), Canary population
has been influenced from Northwest Africa migration and
European colonization (Rando et al. 1999). Differences
among populations were also evident in haplotype analysis,
suggesting that each gene need to be considered individually
to find possible confounding variables that would be crucial
for the interpretation of results. Neither ethnicity nor genetic
endowment of patients is taken into account in clinical trials.
5α-RI arisen as a promise treatment for PCa prevention,
as specific blocker of the enzyme responsible for the synthe-
sis of DHT. We suggest here that SNPs located in SRD5A1
and SRD5A2 may be relevant factors to be considered when
assessing the response to these drugs. Although, both genes
encode for key enzymes in the conversion of testosterone into
DHT and represent attractive targets for preventing prostate
cancer development, they are expressed differentially in
the prostate tissue. Thus, under normal physiologic condi-
tions, SRD5A2 is preferentially expressed over SRD5A1
in the prostate (Thomas et al. 2005; Titus et al. 2005). In
prostate cancer cells, however, the balance in expression of
these genes shift toward predominant expression of SRD5A1
(Titus et al. 2005; Stanbrough et al. 2006), supporting a role
for both enzymes in DHT bioavailability and carcinogene-
sis. However, the importance of androgens in early cancer
initiation is emphasized by the fact that finasteride, a 5-AR
type 2 inhibitor, and dutasteride, a dual 5-AR inhibitor target-
ing both 5-AR type 1 and type 2 enzymes, have been shown
that the risk of prostate cancer incidence reduce by almost
23% (Thompson et al. 2003; Andriole et al. 2010). Since
SRD5A1 and SRD5A2 are differentially expressed and are
blockaded by different drugs, the role of SNPs in each gene
should be studied intensely taking these biological peculiar-
ities in to account. However, the fact that rs523349—a SNP
clearly involved in the success of chemoprevention of CaP
using 5-alpha-reductase inhibitors (Cussenot et al. 2007)—
appeared differentially distributed in our study, reinforce our
findings.
The present study has some limitations that should be
noted. First, to blind the analysis, no clinical data of patients
were available, i.e., there are no data about TNM stag-
ing, tumour grade, biochemical failure, or Gleason Score.
Second, the study was focussed on SRD5A1 and SRD5A2,
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(b)
Figure 1. Box plot of component 1 among the different popula-
tions after PCA for (a) SRD5A1 and (b) SRD5A2.
ignoring possible associations with other genes and polymor-
phisms. Thus, the prostate cancer risk and aggressiveness
conferred by certain SNPs located in 3 beta-hydroxysteroid
dehydrogenase type II (HSD3B2) seem to be modified by
SNPs located in SRD5A2 (Neslund-Dudas et al. 2007). In
the same way, an association between SNPs in CYP17A1
(a gene encoding a key enzyme in the synthesis of andro-
gens) and SRD5A2 has been suggested (Onen et al. 2007).
Third, the number of subjects from different population
varies widely. However, the fact that the main differences
were not found in the population with the smallest number
of patients (Basque Country, with 51 PCa) suggests that this
limitation may not be decisive in the interpretation of results.
On the other hand, some advantages should be high-
lighted: (i) it includes a number of subjects sufficient to have
reliable data on the distribution of these 22 SNPs in the PCa
populations studied (especially for Canary and Catalonia);
(ii) all subjects were male (which is the most interesting
population since the 5α-RI are contraindicated in women),
then avoiding the possible bias generated by the gender; and
(iii) all the determinations (13,222 in total) were performed
with the same methodology, with the same batch of chips and
by the same investigator, thus minimizing biases from tech-
nical origin. All the analyses were automated and there was
no manual assignment of genotypes in any case.
Conclusions
Differences in distribution of genotypes in SRD5A1 and
SRD5A2 within different populations of the same ethnicity
could be an important factor responsible for the failure of
treatments based on 5α-RI. Our results suggest that geno-
typic endowment should be taken into account (especially
in clinical trials including people from different ethnics) in
assessing the effectiveness of these drugs.
Acknowledgements
This work was subsidized by the grant from the Instituto de Salud
Carlos III (Ministerio de Economía y Competitividad from Spain),
ID: PI12/01867. Almudena Valenciano has a grant from the Insti-
tuto Canario de Investigación del Cáncer (ICIC). The founders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript. We thank the technical
support from the Immunology Department (Hospital Universitario
de Gran Canaria, Dr Negrín) staff: Nereida González-Quevedo and
Yanira Florido-Ortega.
References
Ambrosio B., Hernandez C., Novelletto A., Dugoujon J. M.,
Rodriguez J. N., Cuesta P. et al. 2010 Searching the peopling
of the Iberian Peninsula from the perspective of two andalusian
subpopulations: a study based on Y-chromosome haplogroups
J and E. Coll. Antropol. 34, 1215–1228.
Andriole G. L. and Kirby R. 2003 Safety and tolerability of the dual
5alpha-reductase inhibitor dutasteride in the treatment of benign
prostatic hyperplasia. Eur. Urol. 44, 82–88.
Andriole G. L., Bostwick D. G., Brawley O. W., Gomella L. G.,
Marberger M., Montorsi F. et al. 2010 Effect of dutasteride
on the risk of prostate cancer. N. Engl. J. Med. 362, 1192–1202.
Barrett J. C., Fry B., Maller J. and Daly M. J. 2005 Haploview:
analysis and visualization of LD and haplotype maps. Bioinfor-
matics 21, 263–265.
Clayton D. 2012 snpStats: SnpMatrix and XSnpMatrix classes and
methods. R package version 1.8.1. Available at: http://www.
bioconductor.org/packages/release/bioc/html/snpStats.html.
Cussenot O., Azzouzi A. R., Nicolaiew N., Mangin P., Cormier L.,
Fournier G. et al. 2007 Low-activity V89L variant in SRD5A2
is associated with aggressive prostate cancer risk: an explanation
for the adverse effects observed in chemoprevention trials using
5-alpha-reductase inhibitors. Eur. Urol. 52, 1082–1087.
Edwards J. E. and Moore R. A. 2002 Finasteride in the treatment
of clinical benign prostatic hyperplasia: a systematic review of
randomised trials. BMC Urol. 2, 14.
340 Journal of Genetics, Vol. 94, No. 2, June 2015
Pharmacoethnicity of 5-alpha-reductase inhibitors
Giwercman Y. L., Abrahamsson P. A., Giwercman A., Gadaleanu
V. and Ahlgren G. 2005 The 5alpha-reductase type II A49T and
V89L high-activity allelic variants are more common in men with
prostate cancer compared with the general population. Eur. Urol.
48, 679–685.
Henriquez-Hernandez L. A., Valenciano A., Foro-Arnalot P.,
Alvarez-Cubero M. J., Cozar J. M., Suarez-Novo J. F. et al. 2013a
Polymorphisms in DNA-repair genes in a cohort of prostate
cancer patients from different areas in Spain: heterogeneity
between populations as a confounding factor in association
studies. PLoS One 8, e69735.
Henriquez-Hernandez L. A., Valenciano A., Herrera-Ramos E.,
Lloret M., Riveros-Perez A. and Lara P. C. 2013b High-
throughput genotyping system as a robust and useful tool in
oncology: experience from a single institution. Biologicals 41,
424–429.
Huggins C. 1967 Endocrine-induced regression of cancers. Cancer
Res. 27, 1925–1930.
Lindstrom S., Wiklund F., Adami H. O., Balter K. A.,
Adolfsson J. and Gronberg H. 2006 Germ-line genetic varia-
tion in the key androgen-regulating genes androgen receptor,
cytochrome P450, and steroid-5-alpha-reductase type 2 is impor-
tant for prostate cancer development. Cancer Res. 66, 11077–
11083.
Ma Q. and Lu A. Y. 2011 Pharmacogenetics, pharmacog-
enomics, and individualized medicine. Pharmacol. Rev. 63, 437–
459.
McConnell J. D. 1995 Prostatic growth: new insights into hormonal
regulation. Br. J. Urol. 76 suppl 1, 5–10.
Morcillo-Suarez C., Alegre J., Sangros R., Gazave E, de Cid R.,
Milne R. et al. 2008 SNP analysis to results (SNPator): a
web-based environment oriented to statistical genomic analyses
upon SNP data. Bioinformatics 24, 1643–1644.
Neslund-Dudas C., Bock C. H., Monaghan K., Nock N. L., Yang
J. J., Rundle A. et al. 2007 SRD5A2 and HSD3B2 polymor-
phisms are associated with prostate cancer risk and aggressive-
ness. Prostate 67, 1654–1663.
Onen I. H., Ekmekci A., Eroglu M., Polat F. and Biri H. 2007 The
association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase
(CYP17) gene polymorphisms with prostate cancer patients in
the Turkish population. DNA Cell Biol. 26, 100–107.
Rando J. C., Cabrera V. M., Larruga J. M., Hernandez M.,
Gonzalez A. M., Pinto F. et al. 1999 Phylogeographic patterns of
mtDNA reflecting the colonization of the Canary Islands. Ann.
Hum. Genet. 63, 413–428.
Stanbrough M., Bubley G. J., Ross K., Golub T. R., Rubin M. A.,
Penning T. M. et al. 2006 Increased expression of genes
converting adrenal androgens to testosterone in androgen-
independent prostate cancer. Cancer Res. 66, 2815–2825.
Thomas L. N., Lazier C. B., Gupta R., Norman R. W., Troyer D. A.,
O’Brien S. P. et al. 2005 Differential alterations in 5alpha-
reductase type 1 and type 2 levels during development and
progression of prostate cancer. Prostate 63, 231–239.
Thompson I. M., Goodman P. J., Tangen C. M., Lucia M. S.,
Miller G. J., Ford L. G. et al. 2003 The influence of finasteride
on the development of prostate cancer. N. Engl. J. Med. 349,
215–224.
Titus M. A., Gregory C. W., Ford 3rd O. H., Schell M. J.,
Maygarden S. J. and Mohler J. L. 2005 Steroid 5alpha-reductase
isozymes I and II in recurrent prostate cancer. Clin. Cancer Res.
11, 4365–4371.
Walsh P. C. 2010 Chemoprevention of prostate cancer. N. Engl. J.
Med. 362, 1237–1238.
Yasuda S. U., Zhang L. and Huang S. M. 2008 The role of
ethnicity in variability in response to drugs: focus on clinical
pharmacology studies. Clin. Pharmacol. Ther. 84, 417–423.
Received 23 June 2014, in revised form 8 January 2015; accepted 20 January 2015
Unedited version published online: 23 January 2015
Final version published online: 1 June 2015
Journal of Genetics, Vol. 94, No. 2, June 2015 341
